Uterine/Endometrial Cancer Treatment Denied by Insurance: How to Appeal

Uterine (endometrial) cancer is the most common gynecologic cancer in the United States, with approximately 67,000 new cases diagnosed annually. Most cases are caught at an early stage when surgery is curative, but a significant proportion present with advanced or high-grade disease requiring systemic therapy. Pembrolizumab for MSI-H/dMMR endometrial cancer, lenvatinib + pembrolizumab for recurrent disease, and even robotic minimally invasive surgery are among the treatments most frequently denied. This guide explains how to appeal these decisions.

Common Endometrial Cancer Denial Scenarios

Robotic-Assisted Laparoscopic Hysterectomy

For early-stage endometrial cancer, minimally invasive hysterectomy — either laparoscopic or robotic-assisted — is the preferred surgical approach per SGO (Society of Gynecologic Oncology) and NCCN guidelines. Robotic-assisted surgery offers equivalent oncologic outcomes with faster recovery, less blood loss, and lower complication rates than open surgery.

Insurers deny robotic hysterectomy for endometrial cancer by:

• Requiring open (abdominal) hysterectomy as the "standard" despite guidelines favoring minimally invasive approaches
• Calling robotic assistance "not medically necessary" when traditional laparoscopy is available, without considering the surgeon's expertise and the institutional advantages
• Denying robotic surgery based on patient BMI (obesity is highly prevalent in endometrial cancer), despite evidence supporting robotic surgery in high-BMI patients

Pembrolizumab (Keytruda) for MSI-H/dMMR Endometrial Cancer

Pembrolizumab is FDA-approved for:

1. Advanced endometrial carcinoma with MSI-H or dMMR, in combination with lenvatinib, for patients who progressed on prior systemic therapy
2. MSI-H/dMMR endometrial cancer across all lines as single agent (tumor-agnostic approval)
3. First-line therapy in combination with carboplatin + paclitaxel for advanced or recurrent endometrial carcinoma (pMMR and dMMR disease, based on NRG-GY018 and RUBY trials)

Insurers deny pembrolizumab for endometrial cancer by:

• Requiring MMR/MSI testing before approval, then separately denying the MMR/MSI test
• Applying pembrolizumab CPS cutoffs from other cancer types that don't apply to endometrial cancer approvals
• Denying first-line pembrolizumab + carboplatin/paclitaxel by requiring chemotherapy alone first, despite FDA approval for the combination

Lenvatinib + Pembrolizumab (Lenvima + Keytruda)

The combination of lenvatinib (20 mg daily) and pembrolizumab is FDA-approved for advanced endometrial carcinoma that is not MSI-H/dMMR and has progressed following prior systemic therapy. This approval is specifically for pMMR (mismatch repair proficient) disease. Insurers deny this combination by:

• Applying the MSI-H requirement (which applies to single-agent pembro) to the lenvatinib + pembro combination (which is approved regardless of MMR status)
• Requiring failure of two or more prior lines before approving the combination, despite the FDA approval after one prior line
• Denying lenvatinib as a "separate" drug requiring additional Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization

Hormone Therapy for Endometrial Cancer

For recurrent, low-grade endometrial carcinoma in patients who are not surgical candidates, progestin therapy (medroxyprogesterone acetate, megestrol acetate) is an NCCN-listed option. Aromatase inhibitors may also be used. Insurers may deny hormone therapy as "palliative" or "not curative" without recognizing its role in disease control and quality of life.

MSI/MMR Testing

MSI and MMR testing by IHC is now recommended for all endometrial cancers at diagnosis, given its prognostic value and importance for treatment selection (immunotherapy eligibility, Lynch syndrome screening). Insurers may deny:

• Routine MSI/MMR testing at diagnosis as "not yet clinically necessary"
• Reflex Lynch syndrome germline testing triggered by dMMR IHC result (Lynch syndrome affects approximately 3% of endometrial cancer patients)

Lynch Syndrome and BRCA Testing

Endometrial cancer is the most common Lynch syndrome-associated cancer. Reflex germline testing following dMMR IHC in endometrial cancer is now standard at major cancer centers and is recommended by NCCN. The ACA mandate for genetic testing (Section 2713) may apply to qualifying family histories. Insurers may deny germline testing, arguing it is not "medically necessary" for cancer treatment decisions — but Lynch syndrome diagnosis has implications for colon cancer surveillance and family member testing.

Your Legal Rights

ACA essential health benefits: Endometrial cancer treatment is covered with no annual or lifetime dollar limits.

External Independent Review: Complete Guide" class="auto-link">External review: For pembrolizumab and lenvatinib + pembrolizumab denials, external reviewers with gynecologic oncology expertise regularly identify the clinical basis for reversal.

MMR testing as essential companion diagnostic: MMR IHC is now a companion diagnostic for pembrolizumab in endometrial cancer. Denials of MMR testing undermine the ability to determine FDA-approved treatment eligibility.

Building Your Appeal

1. Pathology report: Histology (endometrioid, serous, clear cell, carcinosarcoma), grade, staging, FIGO stage
2. MMR/MSI testing results: IHC for MLH1, MSH2, MSH6, PMS2 — confirming dMMR or pMMR status
3. NCCN Uterine Neoplasms Guidelines: Cite specific recommendations by MMR status and disease stage
4. FDA prescribing information: For pembrolizumab (endometrial cancer indication) and lenvatinib + pembrolizumab
5. Clinical trial publications: NRG-GY018 (pembro + carbo/taxol), RUBY trial, KEYNOTE-146 (lenvatinib + pembro)
6. Letter of medical necessity: From the treating gynecologic oncologist

Fight Back With ClaimBack

ClaimBack helps endometrial cancer patients appeal denials for robotic surgery, pembrolizumab, and targeted therapy. Our platform guides you through the documentation needed to build a compelling, evidence-based appeal.

Start your appeal at ClaimBack

Uterine cancer insurance denials are often based on outdated criteria or misapplied policies. With the right appeal, most are reversible.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied